Karen Liby

Has grant

Professor

Michigan State University

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Karen Liby is a faculty member at Michigan State University in the United States. Her research focuses on cancer biology, particularly the roles of various compounds in modulating immune responses and tumor progression. Recent articles have explored topics such as the impacts of RXR agonists and triterpenoids on tumor burden and immune microenvironment reprogramming in both preclinical models and human conditions.

Recent Grants

Grant: Close

Nrf2, immune cells and lung cancer

Open Date: 2019-04-01

Close Date: 2024-03-31

Grant: Close

Nanoformulations and Sustained Delivery of PARP Inhibitors for Breast Cancer

Open Date: 2016-09-30

Close Date: 2021-09-29

Grant: Close

16K Prolactin as an Angiogenic Inhibitor in Breast Cancer

Open Date: 1997-10-01

Close Date: 1998-09-01

Articles (14)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (3)

Neera Tewari-Singh

Associate Professor

Michigan State University

UNITED STATES

View details

Aaron Odom

Professor

Michigan State University

UNITED STATES

View details

Pamela Marshall

Professor

Arizona State University - West Campus

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Karen Liby

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (14)

The RXR Agonist MSU-42011 Reduces Tumor Burden in a Murine Preclinical NF1-Deficient Model

The BRD4 Inhibitor I-BET-762 Reduces HO-1 Expression in Macrophages and the Pancreas of Mice

The Triterpenoid CDDO-Methyl Ester Reduces Tumor Burden, Reprograms the Immune Microenvironment, and Protects from Chemotherapy-Induced Toxicity in a Preclinical Mouse Model of Established Lung Cancer

KEAP1-Mutant Lung Cancers Weaken Anti-Tumor Immunity and Promote an M2-like Macrophage Phenotype

The Multi-Faceted Consequences of NRF2 Activation throughout Carcinogenesis

Ocular injury progression and cornea histopathology from chloropicrin vapor exposure: Relevant clinical biomarkers in mice.

The Novel RXR Agonist MSU-42011 Differentially Regulates Gene Expression in Mammary Tumors of MMTV-Neu Mice.

The Triterpenoid CDDO-Methyl Ester Redirects Macrophage Polarization and Reduces Lung Tumor Burden in a Nrf2-Dependent Manner.

Exploring structural effects in a new class of NRF2 inhibitors.

T Cells and CDDO-Me Attenuate Immunosuppressive Activation of Human Melanoma-Conditioned Macrophages

The rexinoid V-125 reduces tumor growth in preclinical models of breast and lung cancer

A Novel Nrf2 Pathway Inhibitor Sensitizes Keap1-Mutant Lung Cancer Cells to Chemotherapy

Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting.

Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice

Collaborators (3)

Neera Tewari-Singh

Aaron Odom

Pamela Marshall

Make your next move.